Boehringer Ingelheim Investigational Site

Boston, Massachusetts

0 studies enrolling now · 6 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Diabetes Mellitus, Type 2, Diabetic Nephropathies, HIV Infections, Hypertension, Pulmonary Disease, Chronic Obstructive

Studies at this site

• A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study) — Completed
• Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients — Completed
• 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study — Completed
• Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy — Completed
• A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations — Completed
• Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed